Cytyc ( CYTC), a manufacturer of clinical products that focus on women's health, said its second-quarter earnings rose 13.2% from the year-ago period, helped by strong growth in domestic surgical products and international business. The company earned $31.7 million, or 27 cents a share, in the quarter, compared with $28 million, or 23 cents a share, a year ago. Adjusted for items, earnings were $35.5 million, or 29 cents a share in the most recent quarter. Analysts polled by Thomson First Call were expecting earnings of 26 cents a share. Second-quarter revenue rose 19.9% from a year ago to $150.4 million. Gross profit for the quarter rose 18.1% from a year ago to $117.3 million, however gross margin declined 119 basis points to 78%. Operating income rose 8.2% to $49.9 million, while operating margin dropped 358 basis points to 33.2%. By segment, second-quarter revenue from domestic diagnostic products increased 9% from a year ago to $84.1 million, revenue from domestic surgical products rose 42% to $50 million and revenue from international segment climb 23% to $16.3 million. Shares rose 67 cents Thursday to $24.58.